Clonixin

BRAND NAMES

• Clonix 

• Dolobid (in some regions, though this name can also be associated with diflunisal in certain markets) 

• Clonixina (widely used in parts of Latin America) 

• Clonixin Lysine formulations (often sold under local trade names rather than a single global brand)

MECHANISM OF ACTION

Clonixin is a nonsteroidal anti-inflammatory drug that works by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, which reduces the synthesis of prostaglandins responsible for pain, inflammation, and fever. By lowering prostaglandin levels, it produces analgesic and anti-inflammatory effects, making it useful for treating mild to moderate pain conditions.

PHARMACOKINETICS

Absorption

Clonixin is rapidly absorbed from the gastrointestinal tract after oral administration, reaching peak plasma levels within about 1–2 hours. Although food may slightly delay the rate of absorption, it does not significantly affect overall bioavailability. The drug is highly protein bound in plasma, which contributes to its distribution and duration of action in the body.

Distribution

Clonixin has a moderate volume of distribution (Vd), indicating that it is distributed mainly within the extracellular fluid rather than extensively into tissues. It is highly bound to plasma proteins (mainly albumin), which limits the free fraction of the drug in circulation and influences its distribution and duration of action.

Metabolism

Clonixin is mainly metabolized in the liver through hepatic biotransformation involving oxidation and conjugation reactions. These processes convert the drug into inactive metabolites that are more water-soluble, allowing easier elimination from the body. Cytochrome P450 enzymes may contribute to its metabolic breakdown.

Elimination

Clonixin is eliminated primarily through the kidneys after hepatic metabolism. Most of the drug is excreted in urine as inactive metabolites, with a smaller fraction excreted in feces via biliary elimination. It has a relatively short elimination half-life, which supports multiple daily dosing in clinical use.

PHARMACODYNAMICS

Clonixin exhibits pharmacodynamic actions typical of nonsteroidal anti-inflammatory drugs by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, leading to decreased prostaglandin synthesis. This results in analgesic effects by reducing peripheral pain sensitization, anti-inflammatory effects by limiting vasodilation and edema, and mild antipyretic action through hypothalamic temperature regulation

ADMINISTRATION

Clonixin is most commonly administered orally in tablet form, usually taken with or after food to reduce gastrointestinal irritation. It is used in divided doses depending on the severity of pain, typically for short-term management of acute painful conditions. In some regions, it may also be available in combination formulations, but oral administration remains the primary route.

DOSAGE AND STRENGTH

Clonixin is commonly available in tablet strengths of 125 mg and 250 mg, depending on the formulation and country. In adults, typical dosing for pain relief is usually 125–250 mg taken 2–3 times daily, adjusted based on severity of symptoms and clinical response. It is generally recommended for short-term use at the lowest effective dose to reduce the risk of gastrointestinal and renal adverse effects associated with NSAIDs.

DRUG INTERACTIONS

• With other NSAIDs / aspirin → Increases risk of gastric irritation, ulcers, and bleeding due to additive COX inhibition. 

• With anticoagulants (e.g., warfarin) → Increases bleeding risk by reducing platelet function and damaging gastric mucosa. 

• With antiplatelet drugs (e.g., clopidogrel) → Higher chance of bleeding because both drugs impair clot formation. 

• With corticosteroids → Increased risk of gastrointestinal ulceration and GI bleeding. 

• With antihypertensives (ACE inhibitors, beta-blockers, diuretics) → May reduce their effectiveness by decreasing renal prostaglandins and sodium excretion.

FOOD INTERACTIONS

Clonixin has minimal food interactions. Food may slightly delay its absorption but does not significantly affect its overall effectiveness. Taking it with or after meals is recommended as it helps reduce gastric irritation. Alcohol should be avoided because it can increase the risk of stomach bleeding and irritation.

CONTRAINDICATIONS

Clonixin is contraindicated in patients with hypersensitivity to NSAIDs, active peptic ulcer disease, or a history of gastrointestinal bleeding. It should also be avoided in severe renal or hepatic impairment and in patients with aspirin-sensitive asthma. Use during late pregnancy is not recommended due to potential fetal risks.

SIDE EFFECTS

• Nausea

• Vomiting

• Abdominal pain

• Heartburn

• Gastric irritation / gastritis

OVER DOSE

• Severe nausea and vomiting 

• Abdominal pain 

• Drowsiness or dizziness 

• Tinnitus (ringing in ears) 

• Gastrointestinal bleeding

TOXICITY

Clonixin toxicity occurs mainly in overdose or long-term use. It can cause stomach irritation, ulcers, or bleeding, and may also affect kidney function. In severe cases, it leads to nausea, vomiting, dizziness, and drowsiness.